ESR1 and cancer: The results of the National Cancer Database and the Surveillance, Epidemiology, and End Results (SEER) program indicate that while single ER + or PR + tumor subtypes indicate a worse prognosis than ER+/PR + tumors, ER−/PR + tumors exhibit a similar prognosis to that of the ER−/PR−subtype [14–16].